197 related articles for article (PubMed ID: 19479616)
1. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Ammatuna E; Montefusco E; Pacilli M; Divona M; Ardiri D; Centonze D; Lo-Coco F
Leuk Lymphoma; 2009 Jul; 50(7):1217-8. PubMed ID: 19479616
[No Abstract] [Full Text] [Related]
2. Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Kuriyama K
Intern Med; 2001 Dec; 40(12):1165. PubMed ID: 11813833
[No Abstract] [Full Text] [Related]
3. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
Ramkumar B; Chadha MK; Barcos M; Sait SN; Heyman MR; Baer MR
Cancer Genet Cytogenet; 2008 Apr; 182(2):126-9. PubMed ID: 18406875
[TBL] [Abstract][Full Text] [Related]
4. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.
Cattaneo C; Almici C; Borlenghi E; Motta M; Rossi G
Leukemia; 2003 May; 17(5):985-6. PubMed ID: 12750718
[No Abstract] [Full Text] [Related]
5. Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Taube F; Stölzel F; Thiede C; Ehninger G; Laniado M; Schaich M
Haematologica; 2011 Jun; 96(6):e31. PubMed ID: 21632839
[No Abstract] [Full Text] [Related]
6. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
8. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
[No Abstract] [Full Text] [Related]
9. Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
Au WY; Lang BH; Fong BM; Mao KJ; Tam S
Leuk Lymphoma; 2014 May; 55(5):1184-5. PubMed ID: 23964647
[No Abstract] [Full Text] [Related]
10. Ancient remedy performs new tricks.
Mervis J
Science; 1996 Aug; 273(5275):578. PubMed ID: 8701308
[No Abstract] [Full Text] [Related]
11. Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.
Ravandi F
Leuk Lymphoma; 2009 Jul; 50(7):1073-4. PubMed ID: 19557628
[No Abstract] [Full Text] [Related]
12. Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Perreault S; Moeller J; Patel K; Eyler R; Pham T; Russell K; Podoltsev N
J Oncol Pharm Pract; 2016 Aug; 22(4):646-51. PubMed ID: 25972392
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
[No Abstract] [Full Text] [Related]
14. Treatment of acute promyelocytic leukemia in children: arsenic or ATRA.
Ravindranath Y; Gregory J; Feusner J
Leukemia; 2004 Oct; 18(10):1576-7. PubMed ID: 15356650
[No Abstract] [Full Text] [Related]
15. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.
Novoselac AV; Reddy S; Sanmugarajah J
Leukemia; 2004 Sep; 18(9):1561-2. PubMed ID: 15215874
[No Abstract] [Full Text] [Related]
16. Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Asou N
Intern Med; 2005 Aug; 44(8):775-6. PubMed ID: 16157968
[No Abstract] [Full Text] [Related]
17. Arsenic compound approved as cancer chemotherapy agent.
Miller JL
Am J Health Syst Pharm; 2000 Nov; 57(21):1940, 1942. PubMed ID: 11094644
[No Abstract] [Full Text] [Related]
18. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
19. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
[TBL] [Abstract][Full Text] [Related]
20. Scientists explore use of arsenic in therapy.
Miller M
J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
[No Abstract] [Full Text] [Related]
[Next] [New Search]
